Core Insights - Becton, Dickinson and Company (BDX) has announced a multi-year collaboration with Opentrons Labworks to integrate robotic liquid-handling capabilities into its single-cell multiomics instruments, aiming to automate critical experimental steps for disease research and drug development [1][5][8] - This partnership is expected to enhance BD's Biosciences (BDB) business unit and strengthen its position in the niche market of lab automation [2][8] - Despite the potential benefits of the collaboration, BDX's stock experienced a decline of nearly 1.8% following the announcement [3] Company Performance - BD currently has a market capitalization of $54.19 billion and an earnings yield of 7.8%, which is higher than the industry average of 6.4% [4] - In the last reported quarter, BDX achieved an earnings surprise of 7.6% [4] - Over the past year, BD's shares have decreased by 19.8%, contrasting with a 2.7% rise in the industry and a 17.8% gain in the S&P 500 [10] Partnership Details - The collaboration aims to integrate the BD Rhapsody System with the Opentrons Flex platform, allowing for hands-free workflows in single-cell multiomics experiments [5][6] - An automation-compatible module for the BD Rhapsody System is expected to automate next-generation sequencing library preparation and cell capture [5][6] Industry Prospects - The global sequencing market is projected to grow from $15.54 billion in 2023 to $62.48 billion by 2030, at a CAGR of 22.2%, driven by increasing demand for gene therapy and consumer genomics [7] - The partnership with Opentrons is anticipated to significantly boost BD's business in light of the favorable market conditions [7]